Ozempic vs Wegovy vs Mounjaro: Which GLP-1 Is Right for You?

If you have spent any time researching GLP-1 weight management, you've run into the same confusing wall of brand names: Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Saxenda. Many of them are made by the same company. Some share an active ingredient. Some don't. Some are approved for diabetes but not weight loss. Some are the other way around.

This article sorts it out, honestly and without spin. We will focus on the three you most often hear about together — Ozempic, Wegovy, and Mounjaro — and explain what is actually different between them, what is the same, and how a doctor might decide which to recommend.

The short version

So right away, a few things become clear:

Ozempic and Wegovy are the same molecule — semaglutide — at different dose ranges and with different regulatory labels.

Mounjaro and Zepbound are the same molecule — tirzepatide — at different dose ranges and labels.

Ozempic and Mounjaro are *diabetes* drugs that got famous for weight loss. Wegovy and Zepbound are the same chemistry, approved with the weight-loss label instead.

If you remember nothing else from this article, remember: the molecule matters, the brand name is marketing.

Semaglutide (Ozempic / Wegovy / Rybelsus)

Semaglutide was the first long-acting GLP-1 receptor agonist to become a blockbuster. It works on a single hormone pathway — GLP-1 — and binds to the GLP-1 receptor to slow gastric emptying, suppress appetite, and improve insulin response. We wrote a full mechanism explainer here.

Ozempic is semaglutide approved for type 2 diabetes, sold in doses of 0.25, 0.5, 1, and 2 mg per weekly injection.

Wegovy is the same molecule, titrated higher — up to 2.4 mg per weekly injection — and approved specifically for chronic weight management.

Rybelsus is an oral tablet form of semaglutide. It is less convenient (daily, must be taken on an empty stomach) and generally less effective for weight loss than the injectables, so doctors rarely choose it primarily for weight management.

The pivotal trial for Wegovy was STEP-1, which followed over 1,900 adults with obesity for 68 weeks. Participants on semaglutide 2.4 mg lost substantially more weight than those on placebo. We are deliberately not quoting the specific percentage here because the study average is not a promise to you — your individual result will depend on many factors. But the drug works, and the evidence base is large.

Tirzepatide (Mounjaro / Zepbound)

Tirzepatide is newer and, on paper, more powerful. The difference is that it binds to two hormone receptors at once: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This is called a dual-agonist.

The idea is that GLP-1 alone is powerful but leaves some metabolic levers unpulled. Adding GIP activation appears to amplify the appetite-suppressing and glucose-regulating effects, and in the pivotal SURMOUNT-1 trial (2,539 adults with obesity, 72 weeks), average weight loss on tirzepatide was higher than anything previously seen in a GLP-1 trial.

In practice:

Mounjaro is tirzepatide approved for type 2 diabetes, in doses from 2.5 mg up to 15 mg weekly.

Zepbound is the same molecule with a weight-management label in the United States.

Both are injected once a week, like Ozempic and Wegovy.

Side effects are broadly similar to semaglutide — nausea, constipation, occasional diarrhoea — and some patients report more GI intensity at higher tirzepatide doses. Others report fewer side effects. Individual variation is large.

So which one is "best"?

The honest answer is: there is no universally best GLP-1. There is a best drug for a specific patient based on their health history, availability, budget, and how their body reacts. A doctor deciding between them will usually consider:

1. Is the goal diabetes control, weight management, or both?

If a patient has type 2 diabetes, any of these drugs can help manage blood sugar. If the primary goal is weight loss in someone without diabetes, the weight-approved versions (Wegovy, Zepbound) are the licensed choice — though "off-label" prescribing of Ozempic and Mounjaro for weight loss has been extremely common during the recent GLP-1 boom.

2. What is the patient's side-effect risk profile?

Some patients tolerate semaglutide much better than tirzepatide, and vice versa. There is no reliable way to predict this in advance from a clinical exam alone — which is part of why Magistra built the side-effect predictor that looks at individual characteristics to give a better estimate.

3. What's available and affordable?

This is the part nobody likes to talk about, but it is usually the deciding factor. In some countries only one is reliably stocked. In others, insurance covers one but not the other. In India as of April 2026, generic semaglutide is widely available and dramatically cheaper than branded versions, while tirzepatide is still under patent and costs meaningfully more.

4. Does the patient have other medical conditions?

People with a history of pancreatitis, medullary thyroid cancer, or certain gut conditions may not be suitable candidates for either drug. We have a full article on who should not take GLP-1 medications.

What about Rybelsus, Trulicity, Saxenda?

Quick notes for completeness:

Rybelsus — oral semaglutide. Less effective for weight loss than injections, useful for patients who genuinely cannot tolerate injections.

Trulicity (dulaglutide) — another weekly GLP-1 agonist, older generation, generally less effective than semaglutide for weight loss. Still used widely for diabetes.

Saxenda (liraglutide) — the first-generation GLP-1 weight-loss drug, injected daily. Older, less convenient, but also cheaper and sometimes available when newer drugs are out of stock.

The bottom line

Ozempic and Wegovy are the same molecule — semaglutide — with different labels. Mounjaro and Zepbound are the same molecule — tirzepatide — with different labels. Tirzepatide tends to produce larger average weight loss in trials, but semaglutide is older, more studied, and now available as a much cheaper generic in India.

The best drug for you is the one your doctor chooses based on your health, your tolerance, your goals, and what you can actually access and afford.

If you are trying to research your options before a consultation, the most useful question to ask isn't "which is best" — it is "which is appropriate for me, specifically?" That is a conversation for a qualified doctor, not a marketing brochure.

---

This article is educational and not a substitute for medical advice. Speak to a licensed healthcare provider before starting or changing any medication.

Related reading:

[How Semaglutide Works in Your Body (Without the Hype)](/blog/how-semaglutide-works-in-your-body)

[Who Should NOT Take GLP-1 Weight Loss Medication](/blog/who-should-not-take-glp1)

[Generic Semaglutide vs Ozempic: Is It the Same Medicine?](/blog/generic-semaglutide-vs-ozempic)

Curious about GLP-1 access in India? Learn more about Magistra India.